Get the Stockscreener App
22.92
0.61%
0.14
After Hours:
23.20
0.28
+1.22%
Catalyst Pharmaceuticals Inc stock is traded at $22.92, with a volume of 1.07M.
It is up +0.61% in the last 24 hours and up +7.76% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
See More
Previous Close:
$22.78
Open:
$22.99
24h Volume:
1.07M
Relative Volume:
1.05
Market Cap:
$2.73B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
19.42
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+3.29%
1M Performance:
+7.76%
6M Performance:
+35.30%
1Y Performance:
+57.42%
1-Day Range:
$22.32
$23.15
1-Week Range:
$22.11
$23.26
52-Week Range:
$13.12
$24.27
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
22.92 | 2.73B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
FIRDAPSE now available in Japan for muscle weakness - MSN
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan - The Manila Times
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Up 12.5% in December - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Redhawk Wealth Advisors Inc. Takes $1.27 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
JPMorgan Chase & Co. Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE (NASDAQ:CPRX) - Seeking Alpha
Catalyst Pharmaceuticals (NASDAQ:CPRX) Cut to "Buy" at StockNews.com - MarketBeat
HC Wainwright Issues Positive Forecast for Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price - MarketBeat
Catalyst Settles Patent Fight Against Teva Over Firdapse - Law360
Catalyst Pharmaceuticals' (CPRX) "Buy" Rating Reiterated at Bank of America - MarketBeat
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical - Yahoo Finance
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - MSN
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 13% HigherWhat's Next? - MarketBeat
Catalyst Pharma Gains, Teva Patent Settlement Seen Positive (1) - Bloomberg Law
Catalyst stock climbs 15% on Firdapse litigation settlement - Seeking Alpha
Catalyst Pharmaceuticals Reaches Settlement With Teva in Firdapse Patent Litigation - Marketscreener.com
Catalyst Pharmaceuticals Reaches Settlement Deal With Teva Over Firdapse Patent Litigation - Marketscreener.com
Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva - MarketWatch
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals - The Manila Times
Catalyst Pharmaceuticals reports settlement of Firdapse patent litigation with Teva - TipRanks
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® - GlobeNewswire
Catalyst Pharmaceuticals' (NASDAQ:CPRX) earnings growth rate lags the 37% CAGR delivered to shareholders - Simply Wall St
Oliver Luxxe Assets LLC Purchases 35,225 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Interesting CPRX Call Options For January 17th - Nasdaq
Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by StockNews.com to "Strong-Buy" Rating - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
(CPRX) Long Term Investment Analysis - Stock Traders Daily
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Principal Financial Group Inc. Sells 63,273 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Sanctuary Advisors LLC Acquires Shares of 31,040 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Cut to Buy at StockNews.com - MarketBeat
Catalyst Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - MSN
(CPRX) Investment Analysis and Advice - Stock Traders Daily
Is Catalysts Pharmaceuticals, Inc. (CPRX) the Best Performing Biotech Stock in 2024? - Insider Monkey
Geode Capital Management LLC Sells 34,189 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Barclays PLC - MarketBeat
Wellington Management Group LLP Purchases Shares of 59,584 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease - Simply Wall St
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - MSN
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Sees Large Increase in Short Interest - MarketBeat
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):